Takeda Biopharmaceuticals gets DCGI nod for dengue vaccine QDENGA

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individuals aged four to sixty years old. QDENGA offers protection against all four dengue virus serotypes without prior testing. The vaccine has been approved in forty-three countries since its launch. India accounts for a significant portion of the global dengue burden.